Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies

NCT05705570 is registered in ClinicalTrials.gov with Nelson Hamerschlak as lead sponsor.

NCT NCT05705570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05705570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
Lead sponsor
Nelson Hamerschlak
Phase
Phase 1
Overall status
Recruiting
Start date
February 7, 2023
Completion date
December 1, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia refractory, acute lymphoblastic leukemia, in relapse, b-cell lymphoma recurrent, b-cell lymphoma refractory, chronic lymphocytic leukemia recurrent, chronic lymphocytic leukemia refractory